Novartis drug shows efficacy in chronic urticaria trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. ABBV

Go back to Novartis drug shows efficacy in chronic urticaria trial
NOVARTIS AG (NYSE: NVS) Delayed: 148.64 +1.56 (1.06%)
Previous Close $147.08    52 Week High $89.15 
Open $146.94    52 Week Low $69.84 
Day High $149.23    P/E N/A 
Day Low $146.60    EPS $0.00 
Volume 1,167,057